Condition
EGFR Mutation
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 13 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
13 shownFirst in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)NCT05099172 · 2021-10-25
RECRUITINGA Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung CancerNCT07285148 · 2026-06-01
NOT_YET_RECRUITINGFurmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety StudyNCT07365410 · 2026-01-01
NOT_YET_RECRUITINGIntegrated Genomics in Oncogene-driven NSCLC With Acquired ResistanceNCT07122882 · 2025-09-01
ENROLLING_BY_INVITATIONHigh-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal MetastasisNCT06971406 · 2025-05-15
NOT_YET_RECRUITINGA Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy ParticipantsNCT06360211 · 2024-04-17
COMPLETEDA Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy ParticipantsNCT06348888 · 2024-04-10
COMPLETEDA Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy ParticipantsNCT06378658 · 2024-03-29
COMPLETEDA Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy ParticipantsNCT06329895 · 2024-03-25
COMPLETEDA Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male ParticipantsNCT06221475 · 2024-01-25
COMPLETEDGefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR MutationNCT03486496 · 2018-06-05
UNKNOWNGefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung CancerNCT01951469 · 2016-01-01
UNKNOWNErlotinib 100mg or 150mg in Treating EGFR Mutated NSCLCNCT02140333 · 2013-08-01
UNKNOWNCommon interventions
BAY2927088DRUG4[14C]-BAY2927088 oral solutionDRUG1[14C]-BAY2927088 solution for infusionDRUG1ANS014004 + OsimertinibDRUG1ANS014004 + PLB1004DRUG1BAY2927088 coated tablet 10 mgDRUG1BAY2927088_formulation ADRUG1BAY2927088_formulation B_1DRUG1BAY2927088_formulation B_2DRUG1BAY2927088_formulation B_3DRUG1BerberineDRUG1CarbamazepineDRUG1carboplatinDRUG1Combination therapy prospective cohortDRUG1Dabigatran etexilateDRUG1ErlotinibDRUG1EsomeprazoleDRUG1FoodOTHER1FurmonertinibDRUG1gefitinibDRUG1Gefitinib and Pemetrexed/platinumDRUG1Gefitinib mono-therapyDRUG1ItraconazoleDRUG1MidazolamDRUG1pemetrexedDRUG1
Leading sponsors
Trial status mix
COMPLETED5
NOT_YET_RECRUITING3
UNKNOWN3
ENROLLING_BY_INVITATION1
RECRUITING1
Phase mix
PHASE17
PHASE25
PHASE32
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.